Comparison Overview

Astellas Pharma

VS

AUROBINDO PHARMA LTD

Astellas Pharma

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo, JP, 103-8411
Last Update: 2025-12-09
View Profile
Between 750 and 799
http://www.astellas.com/

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 11,951
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, Telangana, IN, 500032
Last Update: 2025-12-09
Between 750 and 799
https://www.aurobindo.com/

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,616
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Astellas Pharma
100%
Compliance Rate
0/4 Standards Verified
AUROBINDO PHARMA LTD
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Astellas Pharma in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2025.

Incident History — Astellas Pharma (X = Date, Y = Severity)

Astellas Pharma cyber incidents detection timeline including parent company and subsidiaries

Incident History — AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
Incidents

No Incident

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
Incidents

No Incident

FAQ

Astellas Pharma company demonstrates a stronger AI Cybersecurity Score compared to AUROBINDO PHARMA LTD company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, AUROBINDO PHARMA LTD company has disclosed a higher number of cyber incidents compared to Astellas Pharma company.

In the current year, AUROBINDO PHARMA LTD company and Astellas Pharma company have not reported any cyber incidents.

Neither AUROBINDO PHARMA LTD company nor Astellas Pharma company has reported experiencing a ransomware attack publicly.

Neither AUROBINDO PHARMA LTD company nor Astellas Pharma company has reported experiencing a data breach publicly.

Neither AUROBINDO PHARMA LTD company nor Astellas Pharma company has reported experiencing targeted cyberattacks publicly.

Neither Astellas Pharma company nor AUROBINDO PHARMA LTD company has reported experiencing or disclosing vulnerabilities publicly.

Neither Astellas Pharma nor AUROBINDO PHARMA LTD holds any compliance certifications.

Neither company holds any compliance certifications.

Astellas Pharma company has more subsidiaries worldwide compared to AUROBINDO PHARMA LTD company.

AUROBINDO PHARMA LTD company employs more people globally than Astellas Pharma company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Astellas Pharma nor AUROBINDO PHARMA LTD holds SOC 2 Type 1 certification.

Neither Astellas Pharma nor AUROBINDO PHARMA LTD holds SOC 2 Type 2 certification.

Neither Astellas Pharma nor AUROBINDO PHARMA LTD holds ISO 27001 certification.

Neither Astellas Pharma nor AUROBINDO PHARMA LTD holds PCI DSS certification.

Neither Astellas Pharma nor AUROBINDO PHARMA LTD holds HIPAA certification.

Neither Astellas Pharma nor AUROBINDO PHARMA LTD holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A weakness has been identified in itsourcecode Online Pet Shop Management System 1.0. This vulnerability affects unknown code of the file /pet1/addcnp.php. This manipulation of the argument cnpname causes sql injection. The attack can be initiated remotely. The exploit has been made available to the public and could be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A security flaw has been discovered in Tenda AX9 22.03.01.46. This affects the function image_check of the component httpd. The manipulation results in use of weak hash. It is possible to launch the attack remotely. A high complexity level is associated with this attack. It is indicated that the exploitability is difficult. The exploit has been released to the public and may be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 2.6
Severity: HIGH
AV:N/AC:H/Au:N/C:N/I:P/A:N
cvss3
Base: 3.7
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A weakness has been identified in code-projects Student File Management System 1.0. This issue affects some unknown processing of the file /admin/update_student.php. This manipulation of the argument stud_id causes sql injection. The attack is possible to be carried out remotely. The exploit has been made available to the public and could be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A security flaw has been discovered in code-projects Student File Management System 1.0. This vulnerability affects unknown code of the file /admin/save_user.php. The manipulation of the argument firstname results in sql injection. The attack can be executed remotely. The exploit has been released to the public and may be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A vulnerability was identified in code-projects Student File Management System 1.0. This affects an unknown part of the file /admin/update_user.php. The manipulation of the argument user_id leads to sql injection. Remote exploitation of the attack is possible. The exploit is publicly available and might be used.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References